To determine if soluble CD40L multivalency was also important in the tumor immunotherapy setting, established B16F10 tumors were injected peritumorally with PBS alone, control empty expression plasmid pcDNA3.1, or plasmids for the three soluble forms of CD40L: 1-trimer pTr-CD40L; 2-trimer pAcrp30-CD40L; and 4-trimer pSP-D-CD40L. This evidence concerns the gene CD40LG and neoplasm.